Abstract:USP16 is a histone deubiquitinase which facilitates G2/M transition during the cell cycle, regulates DNA damage repair and contributes to inducible gene expression. We mutated the USP16 gene in a high differentiation clone of the acute monocytic leukemia cell line THP-1 using the CRISPR-Cas9 system and generated four homozygous knockout clones. All were able to proliferate and to differentiate in response to phorbol ester (PMA) treatment. One line was highly proliferative prior to PMA treatment and shut down proliferation upon differentiation, like wild type. Three clones showed sustained expression of the progenitor cell marker MYB , indicating that differentiation had not completely blocked proliferation in these clones. Network analysis of transcriptomic differences among wild type, heterozygotes and homozygotes showed clusters of genes that were up- or down-regulated after differentiation in all cell lines. Prior to PMA treatment, the homozygous clones had lower levels than wild type of genes relating to metabolism and mitochondria, including SRPRB , encoding an interaction partner of USP16. There was also apparent loss of interferon signaling. In contrast, a number of genes were up-regulated in the homozygous cells compared to wild type at baseline, including other deubiquitinases ( USP12, BAP1 , and MYSM1 ). However, three homozygotes failed to fully induce USP3 during differentiation. Other network clusters showed effects prior to or after differentiation in the homozygous clones. Thus the removal of USP16 affected the transcriptome of the cells, although all these lines were able to survive, which suggests that the functions attributed to USP16 may be redundant. Our analysis indicates that the leukemic line can adapt to the extreme selection pressure applied by the loss of USP16, and the harsh conditions of the gene editing and selection protocol, through different compensatory pathways. Similar selection pressures occur during the evolution of a cancer in vivo , and our results can be seen as a case study in leukemic cell adaptation. USP16 has been considered a target for cancer chemotherapy, but our results suggest that treatment would select for escape mutants that are resistant to USP16 inhibitors.

The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia

USP15 stabilizes MDM2 to mediate cancer-cell survival and inhibit antitumor T cell responses

Deubiquitinase USP9X Stabilizes RNA M6a Demethylase ALKBH5 and Promotes Acute Myeloid Leukemia Cell Survival.

Inhibition of the Deubiquitinase USP10 Induces Degradation of SYK

3075 – ONCOGENIC DEUBIQUITINATION CONTROLS TYROSINE KINASE SIGNALING AND THERAPY RESPONSE IN ACUTE LEUKEMIA

Deubiquitinase USP28 inhibits ubiquitin ligase KLHL2-mediated uridine-cytidine kinase 1 degradation and confers sensitivity to 5-azacytidine-resistant human leukemia cells

Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia

USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets

USP13 promotes acute myeloid leukemia cell proliferation and autophagy by promoting ATG5

USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism

A Regulatory Network Analysis of the Importance of USP15 in Breast Cancer Metastasis and Prognosis

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia

Disruption of Dntp Homeostasis by Ribonucleotide Reductase Hyperactivation Overcomes AML Differentiation Blockade

USP1 promotes the aerobic glycolysis and progression of T-cell acute lymphoblastic leukemia via PLK1/LDHA axis

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

Inhibition of USP10 Induces Degradation of Oncogenic FLT3.

LncRNA USP30-AS1 promotes the survival of acute myeloid leukemia cells by cis-regulating USP30 and ANKRD13A

[Clinical Significance of USP5 Expression Level in Acute Myeloid Leukemia and Its Regulatory Effects on AKT/mTOR/4EBP1 Signaling Pathway]

Suppression of USP7 Induces BCR-ABL Degradation and Chronic Myelogenous Leukemia Cell Apoptosis

USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression

CRISPR-Cas9 Editing of Human Histone Deubiquitinase Gene USP16 in Human Monocytic Leukemia Cell Line THP-1